Navigation Links
Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Date:12/13/2007

RALEIGH, N.C., Dec. 13 /PRNewswire/ -- The most recent study from the landmark Framingham trial demonstrates the clinical significance of knowing the number of LDL particles (LDL-P) by NMR in the management of a patient's risk for heart disease. This longitudinal outcomes study shows that low levels of LDL particles are associated with fewer cardiovascular disease (CVD) related events than equivalently low levels of LDL cholesterol. The findings confirm that low levels of LDL cholesterol may have limitations and suggests that managing patients to LDL-P targets of therapy may improve patient outcomes.

The NMR LipoProfile test, developed by LipoScience, Inc., is the only test that quantifies the number of LDL particles (LDL-P). LDL particle information is used by clinicians to better manage a patient's cardiovascular health by lowering the number of LDL particles (LDL-P) to acceptable levels using familiar LDL lowering therapies.

Authors, William C. Cromwell, MD, et al, compared the relative ability of LDL cholesterol (LDL-C) and the number of LDL particles (LDL-P), two alternative measures of LDL, to predict cardiovascular disease events at low levels. The study found low numbers of LDL particles, as measured by the NMR LipoProfile test, to be associated with 27% fewer cardiovascular disease events than equivalently low levels of LDL cholesterol. This suggests a clinical role for LDL-P as a treatment target for LDL management.

The authors concluded that because the cholesterol content of LDL particles between individuals is highly variable, LDL cholesterol levels often underestimate the number of LDL particles and a patient's risk for heart disease. In fact, data from another Framingham population showed that 50% of individuals who suffered a heart attack had normal LDL cholesterol levels. Many patients who are being managed to LDL-C targets of therapy, as established by current guidelines, are still at significant risk for cardiovascular disease (CVD). In this study, LDL-P was shown to be a more sensitive indicator of low CVD risk than LDL-C or non-HDL-C, another potential treatment target. The study reinforces the limitations of LDL cholesterol and the importance of managing patients to acceptably low levels of LDL-P to avoid CVD related events such as heart attack.

Data in over 100 published papers reinforce the superior clinical value of the NMR LipoProfile test. These most recent findings were published in the National Lipid Association's December issue of Journal of Clinical Lipidology.

(1) William C. Cromwell, MD, James D. Otvos, PhD et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidology 2007; 1: 583-592.


'/>"/>
SOURCE LipoScience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Sports Legacy Institute Announces Findings of Forensic Examinations on Wrestler Chris Benoits Brain
5. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
6. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Top Washington Health Officials to Honor Framingham Heart Study Participants
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
Breaking Medicine Technology:
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Patients who ... to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics of Westchester. ... for a variety of treatments. One or more sedation methods may be recommended based ...
(Date:5/22/2017)... ... May 22, 2017 , ... “Homeostasis: The Journey of ... to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride that ... the dead of winter and to a dark place where Donald considers suicide. ...
(Date:5/22/2017)... IL (PRWEB) , ... May 22, 2017 , ... ... is part of a larger group investing in InsightRX, an early stage company ... patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel ... created specifically for use in Final Cut Pro X. The business-oriented elements and ... Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look to ...
(Date:5/21/2017)... Georgia (PRWEB) , ... May 21, 2017 , ... For ... designs that cover a wide range of knives and swords, from functional to fantasy. ... deliver the goods with sleek, modern designs that defy tradition. , Offering a range ...
Breaking Medicine News(10 mins):